Michael Cheng, MD, BA

Assistant Professor

Dr. Michael L. Cheng is an academic medical oncologist and Assistant Professor at the University of California, San Francisco (UCSF), where he leads clinical and translational research focused on advancing discoveries in cancer genomics and developing improved therapies for thoracic malignancies, especially Non-Small Cell Lung Cancer (NSCLC). Dr. Cheng received his M.D. from the UCLA David Geffen School of Medicine, where he graduated with Alpha Omega Alpha honors. He completed his residency in Internal Medicine at UCSF and his fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. Prior to returning to UCSF, Dr. Cheng was an Assistant Professor at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Cheng strives to provide individualized, compassionate care with a focus on precision oncology, and continues to be inspired by the tangible and substantial patient benefit driven by research advances. Dr. Cheng sees patients at UCSF Health, and his clinic is located in the Bakar Precision Cancer Medicine Building on the UCSF Mission Bay campus.

Education
- Medical Oncology, Memorial Sloan Kettering Cancer Center
BA, - Molecular and Cell Biology, University of California, Berkeley
MD, - Medicine, University of California, Los Angeles
- Internal Medicine, University of California, San Francisco
Honors and Awards
  • Conquer Cancer Foundation of ASCO Career Development Award
  • Alpha Omega Alpha
  • Conquer Cancer Foundation of ASCO Merit Award
  • PCF Young Investigator Award
  • Phi Beta Kappa
Publications

  1. Cote GM, Kochupurakkal BS, Do K, Bullock A, Cheng ML, Muzikansky A, McLoughlin DE, Cleary JM, Gao X, Parikh A, Park JC, Weekes CD, Yeku O, Zou L, Shapiro GI. A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2024. PMID: 39453756


  2. Baik C, Cheng ML, Dietrich M, Gray JE, Karim NA. Correction to: A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600EMutant Metastatic Non-Small Cell Lung Cancer. Advances in therapy 2024. PMID: 38833145


  3. Baik C, Cheng ML, Dietrich M, Gray JE, Karim NA. A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. Advances in therapy 2024. PMID: 38698170


  4. Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer immunology research 2024. PMID: 38276989


  5. Walmsley CS, Jonsson P, Cheng ML, McBride S, Kaeser C, Vargas HA, Laudone V, Taylor BS, Kappagantula R, Baez P, Richards AL, Noronha AM, Perera D, Berger M, Solit DB, Iacobuzio-Donahue CA, Scher HI, Donoghue MTA, Abida W, Schram AM. Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. NPJ precision oncology 2024. PMID: 38355834


  6. Luo J, Sanchez M, Lee E, Hertzler H, Luong N, Mazzola E, Finstein B, Tamen R, Brisbane G, Nguyen T, Paik PK, Chaft JE, Cheng ML, Khalil H, Piha-Paul SA, Sholl LM, Nishino M, Jänne PA, DuBois SG, Hanna GJ, Shapiro GI, French CA. Initial chemotherapy for locally advanced and metastatic NUT carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023. PMID: 38154515


  7. Sacher A, LoRusso P, Patel MR, Miller WH, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J, GO42144 Investigator and Study Group. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. The New England journal of medicine 2023. PMID: 37611121


  8. Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, Shapiro GI, Park H, Nishino M, Lindsay J, Felt KD, Sharma B, Cherniack AD, Rodig S, Gomez DR, Shaverdian N, Rakaee M, Bandlamudi C, Ladanyi M, Janne PA, Schoenfeld AJ, Sholl LM, Awad MM, Cheng ML. Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023. PMID: 37097610


  9. Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Jänne PA, Coker S, Diamond JR, Hilton J, Shapiro GI, French CA. Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO precision oncology 2023. PMID: 37384867


  10. Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, J?nne PA. Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. Volume 6. JCO precision oncology 2022. PMID: 36455195


  11. Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, ?nsal-Ka?maz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Volume 14 of Issue 17. Cancers 2022. PMID: 36077617


  12. Cheng ML, Thomas V, Vaz N, Hammer MM, Nishino M, Vargas SO, Khalil HA. Lipid pneumonia associated with mineral oil use presenting as fluorine-18-fluorodeoxy-D-glucose-avid lung mass. Volume 15. JTCVS techniques 2022. PMID: 36276695


  13. French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI. Report of the First International Symposium on NUT Carcinoma. Volume 28 of Issue 12. Clinical cancer research : an official journal of the American Association for Cancer Research 2022. PMID: 35417004


  14. Schneider JL, Muzikansky A, Lin JJ, Krueger EA, Lennes IT, Jacobson JO, Cheng M, Heist RS, Piotrowska Z, Gainor JF, Shaw AT, Dagogo-Jack I. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. Volume 3 of Issue 7. JTO clinical and research reports 2022. PMID: 35815322


  15. Cheng ML, Milan MSD, Tamen RM, Bertram AA, Michael KS, Ricciuti B, Kehl KL, Awad MM, Sholl LM, Paweletz CP, J?nne PA. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. Volume 5. JCO precision oncology 2021. PMID: 34994618


  16. Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. Volume 16 of Issue 7. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021. PMID: 33845210


  17. Tsui DWY, Cheng ML, Shady M, Yang JL, Stephens D, Won H, Srinivasan P, Huberman K, Meng F, Jing X, Patel J, Hasan M, Johnson I, Gedvilaite E, Houck-Loomis B, Socci ND, Selcuklu SD, Seshan VE, Zhang H, Chakravarty D, Zehir A, Benayed R, Arcila M, Ladanyi M, Funt SA, Feldman DR, Li BT, Razavi P, Rosenberg J, Bajorin D, Iyer G, Abida W, Scher HI, Rathkopf D, Viale A, Berger MF, Solit DB. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Volume 13 of Issue 1. Genome medicine 2021. PMID: 34059130


  18. Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). Volume 9 of Issue 3. Journal for immunotherapy of cancer 2021. PMID: 33771889


  19. Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, J?nne PA, Oxnard GR, Paweletz CP. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. Volume 5. JCO precision oncology 2021. PMID: 34250387


  20. Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. Volume 71 of Issue 2. CA: a cancer journal for clinicians 2020. PMID: 33165928


  21. Cheng ML, Donoghue MTA, Audenet F, Wong NC, Pietzak EJ, Bielski CM, Isharwal S, Iyer G, Funt S, Bagrodia A, Bajorin DF, Reuter VE, Eng J, Joseph G, Bourque C, Bromberg M, Ling L, Selcuklu SD, Arcila ME, Tsui DWY, Zehir A, Viale A, Berger MF, Bosl GJ, Sheinfeld J, Van Allen E, Taylor BS, Al-Ahmadie H, Solit DB, Feldman DR. Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. Volume 4. JCO precision oncology 2020. PMID: 33163850


  22. Lee Y, Clark EW, Milan MSD, Champagne C, Michael KS, Awad MM, Barbie DA, Cheng ML, Kehl KL, Marcoux JP, Rabin MS, Rotow JK, Sands JM, J?nne PA, Oxnard GR. Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. Volume 4. JCO precision oncology 2020. PMID: 33015530


  23. Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Volume 26 of Issue 15. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32332016


  24. Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Volume 30 of Issue 1. Melanoma research 2020. PMID: 31425479


  25. Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, J?nne PA, Kuo FC, Oxnard GR, Sholl LM. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Volume 140. Lung cancer (Amsterdam, Netherlands) 2019. PMID: 31855703


  26. Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. Tumour lineage shapes BRCA-mediated phenotypes. Volume 571 of Issue 7766. Nature 2019. PMID: 31292550


  27. Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Volume 5 of Issue 4. JAMA oncology 2019. PMID: 30589920


  28. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Volume 34 of Issue 3. Cancer cell 2018. PMID: 30205045


  29. Cheng ML, Oxnard GR. Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC? Volume 25 of Issue 3. Clinical cancer research : an official journal of the American Association for Cancer Research 2018. PMID: 30190372


  30. Cheng ML, Berger MF, Hyman DM, Solit DB. Clinical tumour sequencing for precision oncology: time for a universal strategy. Volume 18 of Issue 9. Nature reviews. Cancer 2018. PMID: 30030494


  31. Cheng ML, Iyer G. Novel biomarkers in bladder cancer. Volume 36 of Issue 3. Urologic oncology 2018. PMID: 29472156


  32. Cheng ML, Solit DB. Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care. Volume 168 of Issue 3. Annals of internal medicine 2018. PMID: 29310131


  33. Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K. The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? Cancer epidemiology 2015. PMID: 25662402


  34. Cheng ML, Fong L. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Current treatment options in oncology 2014. PMID: 24402184


  35. Cheng ML, Fong L. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Frontiers in oncology 2014. PMID: 24432249


  36. Ryan CJ, Cheng ML. Abiraterone acetate for the treatment of prostate cancer. Volume 14 of Issue 1. Expert opinion on pharmacotherapy 2012. PMID: 23199349


  37. Cheng ML, Leibowitz M, Ha E. Coccidioidal endophthalmitis in immunocompetent person, California, USA. Volume 18 of Issue 6. Emerging infectious diseases 2012. PMID: 22608196